Literature DB >> 19491198

Reciprocal effects of STAT5 and STAT3 in breast cancer.

Sarah R Walker1, Erik A Nelson, Lihua Zou, Mousumi Chaudhury, Sabina Signoretti, Andrea Richardson, David A Frank.   

Abstract

Breast cancer is often associated with inappropriate activation of transcription factors involved in normal mammary development. Two related transcription factors, signal transducer and activator of transcription (STAT) 5 and STAT3, play important and distinct roles in mammary development and both can be activated in breast cancer. However, the relative contribution of these STATs to mammary tumorigenesis is unknown. We have found that primary human breast tumors displaying activation of both STATs are more differentiated than those with STAT3 activation alone and display more favorable prognostic characteristics. To understand this difference, we have analyzed the effect of these STATs on gene regulation and phenotype of mammary carcinoma cells. STAT5 and STAT3 mediate opposing effects on several key target genes, with STAT5 exerting a dominant role. Using a model system of paired breast cancer cell lines, we found that coactivation of STAT5 and STAT3 leads to decreased proliferation and increased sensitivity to the chemotherapeutic drugs paclitaxel and vinorelbine compared with cells that have only STAT3 activation. Thus, STAT5 can modify the effects of STAT3 from the level of gene expression to cellular phenotype and analysis of the activation state of both STAT5 and STAT3 may provide important diagnostic and prognostic information in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491198     DOI: 10.1158/1541-7786.MCR-08-0238

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  65 in total

1.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Authors:  Lauren L C Marotta; Vanessa Almendro; Andriy Marusyk; Michail Shipitsin; Janina Schemme; Sarah R Walker; Noga Bloushtain-Qimron; Jessica J Kim; Sibgat A Choudhury; Reo Maruyama; Zhenhua Wu; Mithat Gönen; Laura A Mulvey; Marina O Bessarabova; Sung Jin Huh; Serena J Silver; So Young Kim; So Yeon Park; Hee Eun Lee; Karen S Anderson; Andrea L Richardson; Tatiana Nikolskaya; Yuri Nikolsky; X Shirley Liu; David E Root; William C Hahn; David A Frank; Kornelia Polyak
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.

Authors:  Xiang-Ping Yang; Kamran Ghoreschi; Scott M Steward-Tharp; Jaime Rodriguez-Canales; Jinfang Zhu; John R Grainger; Kiyoshi Hirahara; Hong-Wei Sun; Lai Wei; Golnaz Vahedi; Yuka Kanno; John J O'Shea; Arian Laurence
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

3.  Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Authors:  Thanh U Barbie; Gabriela Alexe; Amir R Aref; Shunqiang Li; Zehua Zhu; Xiuli Zhang; Yu Imamura; Tran C Thai; Ying Huang; Michaela Bowden; John Herndon; Travis J Cohoon; Timothy Fleming; Pablo Tamayo; Jill P Mesirov; Shuji Ogino; Kwok-Kin Wong; Matthew J Ellis; William C Hahn; David A Barbie; William E Gillanders
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

4.  Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.

Authors:  Joomin Lee; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  Carcinogenesis       Date:  2010-08-19       Impact factor: 4.944

5.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

6.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

7.  STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes.

Authors:  Haishan Zhao; Zhe Wang; Huizhe Wu; Qinghuan Xiao; Weifan Yao; Enhua Wang; Yong Liu; Minjie Wei
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

Review 8.  Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.

Authors:  Sarah R Walker; Michael Xiang; David A Frank
Journal:  Mol Cell Endocrinol       Date:  2013-03-24       Impact factor: 4.102

9.  STAT3 protein up-regulates Gα-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis.

Authors:  Ying Dunkel; Andrew Ong; Dimple Notani; Yash Mittal; Michael Lam; Xiaoyi Mi; Pradipta Ghosh
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

10.  Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.

Authors:  Walid Sasi; Wen G Jiang; Anup Sharma; Kefah Mokbel
Journal:  BMC Cancer       Date:  2010-04-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.